



Atty. Dkt. No. 018792-0199

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul Averback

Title: METHODS OF USING NEURAL  
THREAD PROTEINS TO TREAT  
TUMORS AND OTHER  
CONDITIONS REQUIRING THE  
REMOVAL OR DESTRUCTION OF  
CELLS

RECEIVED

1642  
RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Appl. No.: 10/092,934

Filing Date: 03/08/2002

Examiner: Not yet assigned

Art Unit: 1646

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date June 18, 2002

By Michele M. Simkin

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538

Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1419B/PTO

**Complete if Known**

Date Submitted: June 18, 2002

(use as many sheets as necessary)

Sheet

1

9

2

Application Number

10/092.934

Filing Date

03/08/2002

**First Named Inventor**

Paul Averbach

Group Art Unit

1646

Examiner Name

Not Yet Assigned

Attorney Docket Number

018792-0199

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor.

<sup>2</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449B/PTA <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: June 18, 2002 (use as many sheets as necessary)				<b>Complete if Known</b> <b>Application Number</b> 10/092,934 <b>Filing Date</b> 03/08/2002 <b>First Named Inventor</b> Paul Averback Group Art Unit 1646 <b>Examiner Name</b> Not Yet Assigned <b>Attorney Docket Number</b> 018792-0199		<b>RECEIVED</b> AUG 14 2002 TECH CENTER 1600/2900
Sheet	2	of	2			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A-5	de la Monte, Suzanne, et al., <i>AD7c-NTP biomarker for Alzheimer's disease</i> , Alzheimer's Reports, Volume 2, Number 6, pp 327-332 (1999)	Y
	A-6	de la Monte, Suzanne, et al., <i>Characterization of the AD7C-NTP c DNA Expression in Alzheimer's Disease and Measurement of a 41-kD Protein in Cerebrospinal Fluid</i> , J. Clin. Invest., The American Society for Clinical Investigation, Inc., Volume 100, Number 12, pp 3093-3104, December 1997	Y
	A-7	de la Monte, Suzanne, et al., <i>Profiles of Neuronal Thread Protein Expression in Alzheimer's Disease</i> , Journal of Neuropathology and Experimental Neurology, Volume 55, No. 10, pp 1038-1050, October 1996	Y
<p>RECEIVED</p> <p>JUN 19 2007</p> <p>TECH CENTER 1600/2900</p>			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.